Typically supplied in the sodium salt form (CAS number: 76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers. 结构式 药物别名 2-n-propyl-n-valeric acid;2-propyl-pentanoic acid;2-Propylpentanoic Acid;2-...
Valproic acid has been shown to be effective and well tolerated in the treatment of patients with bipolar and schizoaffective disorders, including those resistant to lithium and carbamazepine. When given alone or (more commonly) in combination with other agents in noncomparative studies, it provided...
Immediate release enteric-coated tablet [Canadian product]: 4 hours Valproic acid delayed release capsule: 2 hoursRectal (off-label route): 1 to 3 hours (Graves 1987)Half-Life EliminationIncreased in neonates, elderly, and patients with liver impairment ...
A tablet dosage form of liquid valproic acid (VPA) was formulated using powder solution technology as an alternative to the manufacturing of soft elastic gelatin capsules (SEGs). Mixing of liquid VPA with suitable adsorbents followed by blending with other excipients resulted in a non-adherent, ...
Valproic acid is rapidly absorbed from the gastrointestinal tract, peak concentrations being attained 1 to 2 hours after administration of the conventional tablet, but later with the enteric-coated tablets. The bioavailability of valproi... R Gugler,GE Von Unruh - 《Clinical Pharmacokinetics》 被引...
The teratogenicity of trans-2-ene-valproic acid (300 and 400 mg/kg) was compared with that of valproic acid (VPA; 300 mg/kg) and controls (corn oil) administered by gavage to Sprague-Dawley CD rats on embryonic (E) days 7-18. At the 300 mg/kg dose, trans-2-ene-VPA produced no...
A 60-year-old man treated with valproic acid (VPA) for epilepsy developed atelectasis and respiratory failure after an accidentally aspirated VPA tablet-induced mucus hypersecretion. Following bronchoscopic removal of the aspirated tablet, his respiratory status improved and massive sputum pro...
The invention relates to a heavy-load valproic acid drug sustained release tablet and a preparation method of a heavy-load valproic acid drug sustained release tablet and belongs to the field of pharmaceutical preparations. The heavy-load valproic acid drug sustained release tablet is mainly used ...
Garikipati V,Toops DS,Fang Q.Bioequivalence studies of a new valproic acid delayed-release capsule and divalproex sodium delayed-release tablet.[J].2008,7(7).Bioequivalence studies of a new valproic acid delayed-release capsule and divalproex sodium delayed-release tablet[J] . Vandana Garikipati,...
Formulation of controlled release tablet comprising, a) a compound of valproic acid in an amount of about 40% to about 80% by weight of the dosage form, and b) at least two hydrophilic polymers each in an amount of 10 % to 16% of the weight of the tablet, wherein the valproic acid...